Gene Therapy For Parkinson’s Disease Market Set to Expand Significantly in Terms of Value and CAGR by 2029

 Use Code ONLINE20 to Save 20% On Global Market Reports — Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics

 

 What Is the Growth Potential of the Gene Therapy For Parkinson’s Disease Market Size Over 2025–2034?
 The gene therapy for parkinson’s disease market size has grown exponentially in recent years. It will grow from $0.51 billion in 2024 to $0.64 billion in 2025 at a compound annual growth rate (CAGR) of 26.5%. The growth in the historic period can be attributed to increasing prevalence of parkinson’s disease, rising demand for personalized therapies, growing awareness about gene therapy, expansion of clinical trial networks, and increasing funding for neurodegenerative research.
 
 The gene therapy for parkinson’s disease market size is expected to see exponential growth in the next few years. It will grow to $1.62 billion in 2029 at a compound annual growth rate (CAGR) of 26.1%. The growth in the forecast period can be attributed to growing adoption of viral vector-based therapies, increasing investments in gene therapy startups, rising government support for rare disease treatments, expansion of research collaborations, and growing healthcare infrastructure in emerging markets. Major trends in the forecast period include technological advancements in viral delivery systems, innovations in neurotrophic factor therapies, development of targeted gene-editing constructs, increasing research and development investments, and advancements in precision medicine approaches.
 
 Get your free report sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=28231&type=smp
 
 What Are the Leading Drivers Behind the Growth of the Gene Therapy For Parkinson’s Disease Market?
 The growing interest in personalized medicine is expected to propel the growth of the gene therapy for Parkinson’s disease market going forward. Personalized medicine refers to a medical approach that tailors treatment and prevention strategies to an individual’s genetic makeup, lifestyle, and environment. Interest in personalized medicine is rising due to the growing demand for targeted therapies that improve treatment effectiveness while minimizing adverse side effects. Gene therapy for Parkinson’s disease in personalized medicine is used to deliver tailored genetic modifications that restore dopamine function and address individual patient-specific disease mechanisms. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the US Food and Drug Administration (FDA) granted approval for 16 new personalized treatments for rare disease patients, marking a substantial increase from the 6 approvals in 2022. Therefore, the growing interest in personalized medicine is driving the growth of gene therapy for Parkinson’s disease market.
 
 Which Market Segment Offers the Most Significant Growth Opportunities in the Gene Therapy For Parkinson’s Disease Market?
 The gene therapy for parkinson’s disease market covered in this report is segmented as
 
 1) By Therapy Type: In Vivo Gene Therapy, Ex Vivo Gene Therapy
 2) By Vector Type: Viral Vectors, Non-Viral Vectors
 3) By Target Gene: Aromatic L-Amino Acid Decarboxylase (AADC), Glial Cell Line-Derived Neurotrophic Factor (GDNF), Neurturin, Other Target Genes
 4) By Delivery Method: Intracerebral, Intravenous, Other Delivery Methods
 5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
 
 Subsegment:
 1) By In Vivo Gene Therapy: Viral Vectors, Non-Viral Vectors
 2) By Ex Vivo Gene Therapy: Autologous Cell-Based Gene Therapy, Allogeneic Cell-Based Gene Therapy
 
 What New Market Trends Are Emerging in the Gene Therapy For Parkinson’s Disease Market?
 Major companies are operating in the gene therapy for Parkinson’s disease market, focusing on developing more precise therapy, such as regenerative medicine advanced therapy, to enhance neuronal survival, restore dopamine function, and provide long-lasting disease-modifying benefits for patients with Parkinson’s disease. Regenerative medicine advanced therapy (RMAT) refers to a special United States Food and Drug Administration (FDA) designation granted to regenerative medicine products, such as cell therapies, gene therapies, and tissue-engineered products, that are intended to treat, modify, reverse, or cure serious or life-threatening diseases. For instance, in February 2025, Asklepios BioPharmaceutical, Inc. (AskBio), a US-based gene therapy company, introduced AB-1005, an investigational AAV2-GDNF gene therapy that received FDA regenerative medicine advanced therapy (RMAT) designation. The designation, which is intended to expedite the development and review of promising therapies, was granted based on data submitted by AskBio, including clinical evidence from its Phase Ib open-label, uncontrolled trial, demonstrating AB-1005’s potential to slow disease progression and improve motor function in Parkinson’s patients.
 
 Who Are the Top Industry Players Driving the Gene Therapy For Parkinson’s Disease Market Growth?
 Major companies operating in the gene therapy for parkinson’s disease market are Merck & Co. Inc., Bayer AG, Sanofi S.A., Eli Lilly and Company, Biogen Inc., PTC Therapeutics Inc., Zambon S.p.A., Oxford BioMedica plc, Voyager Therapeutics Inc., Insilico Medicine Inc., Spur Therapeutics Inc., Cerevance Inc., MeiraGTx Holdings plc, BlackfinBio Inc., Partner Therapeutics Inc., Kenai Therapeutics Inc., CureSen Therapeutics Inc., BioVie Inc., Clexio Biosciences Ltd., Tetraneuron S.L.
 
 Get the detailed gene therapy for parkinson’s disease market report today
 https://www.thebusinessresearchcompany.com/report/gene-therapy-for-parkinsons-disease-global-market-report
 
 Which Regional Markets Offer the Most Promising Growth Opportunities for the Gene Therapy For Parkinson’s Disease Market?
 North America was the largest region in the gene therapy for parkinson’s disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gene therapy for parkinson’s disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
 
 Contact Us:
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: info@tbrc.info 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company